SCHEMBL9654452

SCHEMBL9654452

C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(O)C12F

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 7/20 0.79
CYP3A4 P08684 7/20 0.79
LMNA P02545 5/20 0.79
ALDH1A1 P00352 1/20 0.79
NR3C1 P04150 7/20 0.73
HSD17B10 Q99714 4/20 0.73
PGR P06401 4/20 0.73
NFKB1 P19838 3/20 0.73
CYP2C9 P11712 2/20 0.73
PMP22 Q01453 2/20 0.73
CYP2J2 P51589 1/20 0.73
BLM P54132 1/20 0.73
CYP2C19 P33261 1/20 0.73
TSHR P16473 2/20 0.71
AR P10275 2/20 0.71
MEN1 O00255 1/20 0.71
CYP2D6 P10635 1/20 0.71
KMT2A Q03164 1/20 0.71
APEX1 P27695 1/20 0.71
NPSR1 Q6W5P4 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94367 1.00 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL17884670 1.00 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL13657566 1.00 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL17665286 1.00 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL3764416 1.00 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL19715951 1.00 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL1122877 1.00 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL11856116 0.92 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL11856120 0.92 HIF1A (0.79) HIF1ACYP3A4LMNAALDH1A1NR3C1
SCHEMBL11845795 0.91 CYP3A4 (0.77) HIF1ACYP3A4LMNAALDH1A1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220249436-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC (US) 2022-08-11 US disclosed
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity Zander Biologics, Inc (US) 2022-07-05 US disclosed
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans KCL THERAPEUTICS, INC. (US) 2022-05-10 US disclosed
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS Zander Therapeutics, Inc. (US) 2020-03-05 US disclosed
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals Zander Therapeutics, Inc. (US) 2019-11-12 US disclosed
WO-2019104201-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS Zander Therapeutics, Inc. (US) 2019-05-31 WO disclosed
WO-2019104199-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY REGEN BIOPHARMA INC. (US) 2019-05-31 WO disclosed
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals Zander Therapeutics, Inc. 2019-02-21 US disclosed
US-20180346456-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY SYBLEU INC. 2018-12-06 US disclosed
US-20180346455-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS SYBLEU INC. 2018-12-06 US disclosed
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 US disclosed
WO-2017218815-A1 MOTOR-ASSOCIATED NEURODEGENERATIVE DISEASE AND METHODS OF TREATMENT Verge Analytics, Inc. (US) 2017-12-21 WO disclosed
US-20170360805-A1 MOTOR-ASSOCIATED NEURODEGENERATIVE DISEASE AND METHODS OF TREATMENT Verge Analytics, Inc. 2017-12-21 US disclosed
EP-0301966-B1 PHARMACEUTICAL COMPOSITIONS FOR TREATING DEGENERATIVE JOINT DISEASE Trager, Seymour F. (US) 1992-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 HIF1A 1900/4885CYP3A4 3020/4885LMNA 4829/4885
US-20180346455-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 HIF1A 1853/4885CYP3A4 3544/4885LMNA 4829/4885
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 HIF1A 1853/4885CYP3A4 3544/4885LMNA 4829/4885
US-20220249436-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 HIF1A 1900/4885CYP3A4 3020/4885LMNA 4829/4885
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals NR4A2, NR2C2, NR0B2 HIF1A 1853/4885CYP3A4 3544/4885LMNA 4829/4885
US-20170360805-A1 MOTOR-ASSOCIATED NEURODEGENERATIVE DISEASE AND METHODS OF TREATMENT TARDBP, SMN1; SMN2, GRN HIF1A 4474/4885CYP3A4 4778/4885LMNA 1054/4885
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans NR4A2, NR2C2, NR0B2 HIF1A 1900/4885CYP3A4 3020/4885LMNA 4829/4885
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity NR4A2, NR2C2, NR2F2 HIF1A 2074/4885CYP3A4 3450/4885LMNA 4840/4885
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals NR4A2, NR2C2, NR0B2 HIF1A 1853/4885CYP3A4 3544/4885LMNA 4829/4885
US-20180346456-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY NR4A2, NR2C2, NR2F2 HIF1A 2074/4885CYP3A4 3450/4885LMNA 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.